Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Prostate Cancer
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
Opinion: Understanding the FDA’s Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
Identifying Molecular Determinants of Response to Apalutamide
Felix Y. Feng, MD, discusses his presentation at the American Society of Oncology Genitourinary Symposium 2019 meeting.
Investigational Antiandrogen Drug Delays Metastasis in CRPC
Among men with nonmetastatic castration-resistant prostate cancer, those who were treated with darolutamide had a 59% decreased risk of metastasis compared with placebo recipients.
Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer
At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.
Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.
Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
At 23 years of follow-up, the cumulative incidence of death was higher among patients in the watchful waiting group compared with those in the radical prostatectomy group.
Newer mCRPC Drugs Led to Longer Survival in African American Patients
The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.
Metastatic Prostate Cancer Responds to Novel Radiation Therapy
By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
Next post in Genitourinary Cancers Symposium 2019
